Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Synthetic Biologics has announced that the US Patent and Trademark Office has issued US Patent No. 8,658,627 entitled, Pregnancy Hormone Combination for Treatment of Autoimmune Diseases, to the Regents of the University of California (UCLA).
Subscribe to our email newsletter
The patent includes claims to the use of the company’s drug candidate, Trimesta (oral estriol), in conjunction with a gestagen for the treatment of multiple sclerosis (MS) and other autoimmune diseases.
The patent also includes a claim for the administration of Trimesta, a gestagen and a third standard of care MS agent, such as glatiramer acetate injection (Copaxone), interferon beta-1a (Avonex, Rebif), interferon beta-1b (Betaseron, Extavia) or sphingosine-1-phosphate receptor modulator (Gilenya).
Through its wholly owned subsidiary, Synthetic Biologics holds the exclusive license to the newly issued US Patent 8,658,627, as well as US Patents 8,372,826 and 6,936,599 and pending patents for MS and other autoimmune diseases covering the uses of its oral estriol candidate, Trimesta.
In an on-going randomized, double-blind, placebo-controlled Phase II clinical trial for the treatment of women with relapsing-remitting MS, patients enrolled at 15 centers in the US are administered either Trimesta in combination with Copaxone® and progesterone (a gestagen), or receive a placebo plus Copaxone.
Lead Principal Investigator of the clinical trial, Dr Rhonda Voskuhl, Professor, Department of Neurology, Jack H. Skirball Chair in Multiple Sclerosis Research and director, Multiple Sclerosis Program at the UCLA School of Medicine, is scheduled to present topline results from this trial at the American Academy of Neurology’s (AAN) 66th Annual Meeting in Philadelphia on 29 April and 30 April 2014, as part of the AAN Emerging Science program.
The clinical trial is supported by grants exceeding $8m, awarded primarily by the National Multiple Sclerosis Society (NMSS) in partnership with the NMSS’s Southern California chapter, and the National Institutes of Health.
Synthetic Biologics CEO Jeffrey Riley noted claims in this new patent further expand Synthetic Biologics’ intellectual property related to our oral estriol candidate, Trimesta, for the treatment of MS and other autoimmune diseases.
"Our objective has been to continue to strengthen our intellectual property covering oral estriol and this patent is an achievement in that direction," Riley added.